Consistent with longer survival being a consequence of a reduction in tumor burden, flow cytometric analysis of the intrafemoral bone marrow taken on day 28 during treatment (Figure 6C) showed a reduction in transplanted MV4;11 (human CD45+) cells when compared with controls. The gene discussed is PTPRC; the disease is neoplasm.